PMID- 38025173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2155-0417 (Electronic)
IS  - 2155-0417 (Linking)
VI  - 14
IP  - 2
DP  - 2023
TI  - Prevalence of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitor Prescribing in 
      Patients with Type 2 Diabetes Mellitus and Reduced Estimated Glomerular 
      Filtration Rate.
LID - 10.24926/iip.v14i2.5456 [doi]
AB  - Sodium glucose cotransporter 2 (SGLT-2) inhibitors have demonstrated benefit in 
      people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), 
      including slowing the progression of CKD and lowering the risk of kidney failure 
      and death. Despite this evidence, literature suggests SGLT-2 inhibitors are 
      underutilized in this population. To assess prescribing practices and identify 
      potential variables predictive of SGLT-2 inhibitor prescribing, a 
      non-interventional, retrospective, cross-sectional study was conducted in 
      patients with T2DM and reduced estimated glomerular filtration rate (eGFR). The 
      primary outcome compared prevalence of SGLT-2 inhibitor prescribing in patients 
      with T2DM and eGFR of 30-44 mL/min/1.73m(2) to patients with T2DM and eGFR 
      45-59 mL/min/1.73m(2). The secondary outcome described possible predictors of 
      prescribing SGLT-2 inhibitors in this population. Of the 9,387 patients 
      identified with T2DM and reduced eGFR, an SGLT-2 inhibitor was prescribed to 324 
      (12.2%) patients with eGFR of 30-44 mL/min/1.73m(2) versus 799 (11.9%) patients 
      with eGFR of 45-59 mL/min/1.73m(2). Patients more likely to be prescribed SGLT-2 
      inhibitors were younger, male, had a higher body mass index (BMI), a higher 
      hemoglobin A1c (HbA1c), were on other antihyperglycemic medications, had 
      concomitant cardiovascular disease, or had concomitant heart failure. This study 
      found no significant difference in prevalence of SGLT-2 inhibitor prescribing 
      between patients with T2DM and eGFR 30-44 mL/min/1.73m(2) versus eGFR 
      45-59 mL/min/1.73m(2) (p=0.70). Further exploration into the causes of low SGLT-2 
      inhibitor prescribing prevalence is warranted given the growing evidence 
      supporting the use of these agents in patients with T2DM and reduced renal 
      function.
CI  - (c) Individual authors.
FAU - Chonko, Kayla
AU  - Chonko K
AD  - Pharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, 
      Cleveland, Ohio, 44195.
FAU - Russo-Alvarez, Giavanna
AU  - Russo-Alvarez G
AD  - Pharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, 
      Cleveland, Ohio, 44195.
FAU - Isaacs, Diana
AU  - Isaacs D
AD  - Pharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, 
      Cleveland, Ohio, 44195.
FAU - Wang, Lu
AU  - Wang L
AD  - Quantitative Health Sciences Department, Lerner Research Institute, Cleveland 
      Clinic, Cleveland, Ohio.
FAU - Soric, Amanda
AU  - Soric A
AD  - Pharmacy Department, Cleveland Clinic, Cleveland, Ohio, 9500 Euclid Ave, 
      Cleveland, Ohio, 44195.
LA  - eng
PT  - Journal Article
DEP - 20231010
PL  - United States
TA  - Innov Pharm
JT  - Innovations in pharmacy
JID - 101574764
PMC - PMC10653713
OTO - NOTNLM
OT  - Type 2 diabetes
OT  - chronic kidney disease (CKD)
OT  - prescribing prevalence
OT  - sodium-glucose cotransporter-2 (SGLT-2) inhibitors
EDAT- 2023/11/29 18:43
MHDA- 2023/11/29 18:44
PMCR- 2023/10/10
CRDT- 2023/11/29 16:23
PHST- 2023/11/29 18:44 [medline]
PHST- 2023/11/29 18:43 [pubmed]
PHST- 2023/11/29 16:23 [entrez]
PHST- 2023/10/10 00:00 [pmc-release]
AID - 10.24926/iip.v14i2.5456 [doi]
PST - epublish
SO  - Innov Pharm. 2023 Oct 10;14(2):10.24926/iip.v14i2.5456. doi: 
      10.24926/iip.v14i2.5456. eCollection 2023.